Quarterly report · Q1
4671.TEDINET S100OZLA
Period2022-04-01 → 2022-06-30
Filed2022-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 34
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥11.6bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥50.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥12.0bn | 2021-04-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | ¥681m | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | ¥1.3bn | 2021-04-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | ¥769m | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥5.8bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.3bn | 2021-04-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥748m | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥1.3bn | 2021-04-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥442m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥845m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥442m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | ¥845m | 2021-04-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥38.2bn | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥40.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥37.7bn | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥14.6bn | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥16.8bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥23.6bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥23.5bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥21.0bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥9.6bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥10.6bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥42.32 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥339 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥81.41 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥42.25 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥336.99 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥81.28 | 2021-04-01 → 2021-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 61.5% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.1% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.5% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥4m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥4m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥108m |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥7.7bn |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥7.7bn |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥3m |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥782m |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥3.9bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥3.9bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥0 |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥6m |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥11.6bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥11.6bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥4m |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥789m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-06-30 | −¥4m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-06-30 | −¥4m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | −¥84m |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥8.0bn |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥8.0bn |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥3m |
| jpcrp040300-q1r_E04982-000Clinical Testing Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥1.3bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥4.0bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥4.0bn |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥0 |
| jpcrp040300-q1r_E04982-000Dispensing Pharmacy Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥102m |
| —segment total | revenue | 2021-04-01 → 2021-06-30 | ¥12.0bn |
| —segment total | revenue external | 2021-04-01 → 2021-06-30 | ¥12.0bn |
| —segment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥4m |
| —segment total | segment profit | 2021-04-01 → 2021-06-30 | ¥1.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 352
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)ＰｗＣ 京 都 監 査 法 人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)松 永 幸 廣 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)浦 上 卓 也 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 12021000000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 11566000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 50007000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 1335000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 769000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 5809000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 845000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 442000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 3533000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 792000000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 495000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 3468000000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 20991000000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 23618000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 23478000000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 37658000000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 38239000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 40256000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 81.41 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 42.32 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 339.00 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | 81.28 | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | 42.25 | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | 336.99 | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.555 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.615 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.581 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 11280177 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 11280177 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 11280177 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 11280177 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 757900 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 10497900 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 104979 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 24377 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 11280177 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 104979 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 757900 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 757900 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0672 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |